Clinical trial · Observational
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Prostate Cancer VTE in Sweden: Epidemiology and Anticoagulation Treatment of VTE
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary embolism) and is a leading cause of condition of being diseased and death among cancer patients. The goal of the study is to gather information how often venous thromboembolism (VTE) occurs in prostate cancer patients in Sweden and how this condition is treated with blood thinners.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Venous Thromboembolism (VTE) | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apixaban(Eliquis) | Drug | — | UNRESOLVED |
| Pradaxa (Dabigatran etexilate) | Drug | — | UNRESOLVED |
| Rivaroxaban (Xarelto, BAY59-7939) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Men with Prostate Cancer (PCa)
- interventionNames
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
- Drug: Apixaban(Eliquis)
- Drug: Pradaxa (Dabigatran etexilate)
- label
- Men without PCa
Primary outcomes (9)
- measure
- Subject's socio-demographic at the date of an incident PCa diagnosis
- timeFrame
- Retrospective analysis between 2007 and 2016
- description
- Among men with PCa
- measure
- Subject's clinical characteristics at the date of an incident PCa diagnosis
- timeFrame
- Retrospective analysis between 2007 and 2016
- description
- Among men with PCa
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Initially all patients newly diagnosed with PCa between 2007-2016 with at least one year before the end of follow up date (31 December 2017) will be included. From this population, a sub-population of PCa patients with a first cancer-related VTE event will be selected. Exclusion Criteria: * None
References
Publications (0)
Data not yet available